Discovery of HSPG2 (Perlecan) As a Therapeutic Target in Triple Negative Breast Cancer

Overview

Journal Sci Rep

Specialty Science

Date 2019 Aug 30

PMID 31462656

Citations 25

Authors

Stephen Kalscheuer

Vidhi Khanna

Hyunjoon Kim

Sihan Li

Deepali Sachdev

Arthur DeCarlo

Da Yang

Jayanth Panyam

Affiliations

Soon will be listed here.

Abstract

In recent years, there have been significant advances in the treatment of breast cancer resulting in remarkably high survival rates. However, treatment options for metastatic triple negative breast cancer (TNBC) are quite limited due to a lack of identifiable, unique markers. Using a phage display-based whole cell biopanning procedure, we developed two human antibodies that bind to tumor cells with a metastatic TNBC phenotype. Our studies further identified domain 1 of HSPG2 (perlecan) protein as the cognate cell surface antigen bound by the antibody. Immunohistochemistry studies utilizing patient tissue samples revealed significant cell surface expression of HSPG2 in both primary tumors and metastatic lesions. Further, higher HSPG2 expression correlated with poor survival in TNBC. The affinity-matured antibody inhibited the growth of triple negative MDA-MB-231 tumors to a greater extent in nude mice than in NSG mice, pointing to the potential role of natural killer cell-mediated antibody-dependent cell cytotoxicity. This mechanism of action was confirmed through in vitro assays using mouse splenocytes and human peripheral blood mononuclear cells (PBMCs). These results suggest that HSPG2 is a promising target in metastatic TNBC and HSPG2-targeted antibodies could represent a potentially novel class of targeted therapeutics for TNBC.

Citing Articles

Comprehensive pan-cancer analysis of HSPG2 as a marker for prognosis.

Chen F, Gu X, Qiang G BMC Med Genomics. 2025; 18(1):33.

PMID: 39956899 PMC: 11831783. DOI: 10.1186/s12920-025-02103-w.

Proteoglycans in Mechanobiology of Tissues and Organs: Normal Functions and Mechanopathology.

Farach-Carson M, Wu D, Franca C Proteoglycan Res. 2024; 2(2).

PMID: 39584146 PMC: 11584024. DOI: 10.1002/pgr2.21.

Identification of HSPG2 as a bladder pro-tumor protein through NID1/AKT signaling.

Li C, Luo P, Guo F, Jia X, Shen M, Zhang T Cancer Cell Int. 2024; 24(1):345.

PMID: 39438949 PMC: 11515648. DOI: 10.1186/s12935-024-03527-7.

Dimension reduction, cell clustering, and cell-cell communication inference for single-cell transcriptomics with DcjComm.

Ding Q, Yang W, Xue G, Liu H, Cai Y, Que J Genome Biol. 2024; 25(1):241.

PMID: 39252099 PMC: 11382422. DOI: 10.1186/s13059-024-03385-6.

Tunable Hybrid Hydrogels of Alginate and Cell-Derived dECM to Study the Impact of Matrix Alterations on Epithelial-to-Mesenchymal Transition.

Barros da Silva P, Zhao X, Bidarra S, Nascimento D, LaLone V, Lourenco B Adv Healthc Mater. 2024; 13(29):e2401032.

PMID: 39246099 PMC: 11582509. DOI: 10.1002/adhm.202401032.

References

Carey L, Rugo H, Marcom P, Mayer E, Esteva F, Ma C . TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol. 2012; 30(21):2615-23. PMC: 3413275. DOI: 10.1200/JCO.2010.34.5579. View

Grindel B, Martinez J, Pennington C, Muldoon M, Stave J, Chung L . Matrilysin/matrix metalloproteinase-7(MMP7) cleavage of perlecan/HSPG2 creates a molecular switch to alter prostate cancer cell behavior. Matrix Biol. 2014; 36:64-76. PMC: 4748839. DOI: 10.1016/j.matbio.2014.04.005. View

Dent R, Trudeau M, Pritchard K, Hanna W, Kahn H, Sawka C . Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007; 13(15 Pt 1):4429-34. DOI: 10.1158/1078-0432.CCR-06-3045. View

DeCarlo A, Belousova M, Ellis A, Petersen D, Grenett H, Hardigan P . Perlecan domain 1 recombinant proteoglycan augments BMP-2 activity and osteogenesis. BMC Biotechnol. 2012; 12:60. PMC: 3485628. DOI: 10.1186/1472-6750-12-60. View

Lu H, Yang Y, Gad E, Inatsuka C, Wenner C, Disis M . TLR2 agonist PSK activates human NK cells and enhances the antitumor effect of HER2-targeted monoclonal antibody therapy. Clin Cancer Res. 2011; 17(21):6742-53. PMC: 3206987. DOI: 10.1158/1078-0432.CCR-11-1142. View

Wild R, Fager K, Flefleh C, Kan D, Inigo I, Castaneda S . Cetuximab preclinical antitumor activity (monotherapy and combination based) is not predicted by relative total or activated epidermal growth factor receptor tumor expression levels. Mol Cancer Ther. 2006; 5(1):104-13. DOI: 10.1158/1535-7163.MCT-05-0259. View

Slamon D, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A . Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344(11):783-92. DOI: 10.1056/NEJM200103153441101. View

Balko J, Giltnane J, Wang K, Schwarz L, Young C, Cook R . Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer Discov. 2013; 4(2):232-45. PMC: 3946308. DOI: 10.1158/2159-8290.CD-13-0286. View

Iozzo R, Cohen I, Grassel S, Murdoch A . The biology of perlecan: the multifaceted heparan sulphate proteoglycan of basement membranes and pericellular matrices. Biochem J. 1994; 302 ( Pt 3):625-39. PMC: 1137278. DOI: 10.1042/bj3020625. View

10.

Elenbaas B, Spirio L, Koerner F, Fleming M, Zimonjic D, Donaher J . Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Genes Dev. 2001; 15(1):50-65. PMC: 312602. DOI: 10.1101/gad.828901. View

11.

Arnould L, Gelly M, Penault-Llorca F, Benoit L, Bonnetain F, Migeon C . Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?. Br J Cancer. 2006; 94(2):259-67. PMC: 2361112. DOI: 10.1038/sj.bjc.6602930. View

12.

Richardson T, Trinkaus-Randall V, Nugent M . Regulation of heparan sulfate proteoglycan nuclear localization by fibronectin. J Cell Sci. 2001; 114(Pt 9):1613-23. DOI: 10.1242/jcs.114.9.1613. View

13.

Aviezer D, Iozzo R, Noonan D, Yayon A . Suppression of autocrine and paracrine functions of basic fibroblast growth factor by stable expression of perlecan antisense cDNA. Mol Cell Biol. 1997; 17(4):1938-46. PMC: 232040. DOI: 10.1128/MCB.17.4.1938. View

14.

Jiang G, Zhang S, Yazdanparast A, Li M, Pawar A, Liu Y . Comprehensive comparison of molecular portraits between cell lines and tumors in breast cancer. BMC Genomics. 2016; 17 Suppl 7:525. PMC: 5001206. DOI: 10.1186/s12864-016-2911-z. View

15.

Mani S, Guo W, Liao M, Eaton E, Ayyanan A, Zhou A . The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133(4):704-15. PMC: 2728032. DOI: 10.1016/j.cell.2008.03.027. View

16.

Whitelock J, Graham L, Melrose J, Murdoch A, Iozzo R, Underwood P . Human perlecan immunopurified from different endothelial cell sources has different adhesive properties for vascular cells. Matrix Biol. 1999; 18(2):163-78. DOI: 10.1016/s0945-053x(99)00014-1. View

17.

Bazan J, Calkosinski I, Gamian A . Phage display--a powerful technique for immunotherapy: 1. Introduction and potential of therapeutic applications. Hum Vaccin Immunother. 2012; 8(12):1817-28. PMC: 3656071. DOI: 10.4161/hv.21703. View

18.

Wang Z, Manabe T, Ohshio G, Imamura T, Yoshimura T, Suwa H . Immunohistochemical study of heparan sulfate proteoglycan in adenocarcinomas of the pancreas. Pancreas. 1994; 9(6):758-63. DOI: 10.1097/00006676-199411000-00015. View

19.

Kovalszky I, Hjerpe A, Dobra K . Nuclear translocation of heparan sulfate proteoglycans and their functional significance. Biochim Biophys Acta. 2014; 1840(8):2491-7. DOI: 10.1016/j.bbagen.2014.04.015. View

20.

Niwa R, Sakurada M, Kobayashi Y, Uehara A, Matsushima K, Ueda R . Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density. Clin Cancer Res. 2005; 11(6):2327-36. DOI: 10.1158/1078-0432.CCR-04-2263. View